One study exploring the treatment of BRAF-mutated CRC using a xenograft model, found that both pyrvinium and axitinib were able to significantly increase the ability of vemurafenib to attenuate tumor growth in xenografts of BRAF-mutated colorectal cancer cells. This evidence concerns the gene BRAF and colorectal carcinoma.